Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, will participate at the XXXV Congress of the
European Society of Cataract and Refractive Surgeons (ESCRS), Europe's
leading organization for cataract and refractive surgeons, to be held in
Lisbon, Portugal on October 7th through 11th.
The Presbia Flexivue Microlens is currently approved for sale in 42
countries around the world. The company is planning to make its final
submission to the FDA before the end of 2017 in anticipation of approval
in 2018. Several surgeons who have implanted the Presbia Flexivue
Microlens commercially and as part of the FDA study will be sharing
their hands-on experience with the product at ESCRS.
Prof. Tae Young Chung, who is conducting a clinical study with the
Presbia Flexivue Microlens at Samsung Medical Center in South Korea,
will present at the ESCRS congress.
Prof. Pallikaris, who has experience with the Presbia Flexivue Microlens
since 2007, is participating in an Instructional Course titled "Corneal
Inlay Technologies for the Treatment of Presbyopia".
On October 5th, Dr. Fantozzi, who first performed the Presbia
Flexivue Microlens procedure over seven years ago, will present
long-term results at the Presbymania event, an event where experts from
around the world gather to discuss the surgical treatment of presbyopia.
Dr. Karl Stonecipher, a clinical investigator who is participating in
the FDA pivotal study of the Presbia Flexivue Microlens, will also
conduct a presentation at the International Society of Presbyopia (ISOP)
that is being held at the Saba Lisboa Hotel on October 6th in
Mr. Todd Cooper, President and CEO of Presbia will give a presentation
at the Ophthalmology Futures European Forum, focusing on the
transformation of presbyopia correction with the Presbia Flexivue
Microlens. This will take place on Thursday, October 5th at
the Myriad Crystal Center, Lisbon, Portugal.
"Presbia's presentations being held at ESCRS and at ISOP will increase
industry leaders' awareness of the positive results that have been
consistently reported globally by surgeons and patients using our
Microlens as the treatment for near-vision loss," said Todd Cooper,
President and CEO of Presbia. "Surgeons will have an opportunity for
hands-on experience with our product at the Presbia booth, enabling them
to experience our unique presbyopia solution."
Presbia representatives will be available for one-on-one meetings at
booth number P288 during the ESCRS.
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
Such forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form 10-Q and
other reports we file with the Securities and Exchange Commission.
Accordingly, you are cautioned that any such forward-looking statements
are not guarantees and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Although Presbia believes
that the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Unless otherwise required by law, Presbia
also disclaims any obligation to update its view of any such risks or
uncertainties or to announce publicly the result of any revisions to the
forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005674/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media